Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma
Status:
Terminated
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to test the combination of Gleevec® (also known as imatinib
mesylate) and Taxotere (also known as docetaxel) in patients with incurable stomach cancer.
This study is being performed to see if the combination of Gleevec and Taxotere is an
effective treatment for incurable stomach cancer with minimal side effects.